BCG therapy is an immunotherapy for bladder cancer that uses bacteria to activate the immune system and help prevent cancer from returning.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients more hope ...

The FDA approved Imfinzi with chemotherapy for neoadjuvant treatment in muscle invasive bladder cancer, followed by adjuvant Imfinzi post-cystectomy. The phase 3 NIAGARA trial demonstrated significant ...

“It’s an example of a therapy that was proven to be clinically effective before we fully understood all the underlying mechanisms,” says physician-scientist Michael Glickman, MD, acting director of ...

Unlike conventional bladder cancer, which has a consistent look under the microscope and succumbs predictably to therapy, the deadliest bladder tumors, collectively known as histologic variant (HV ...

Among patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant cisplatin-based combination chemotherapy (NAC) plus bladder-saving concurrent chemoradiation ...

A paradigm shift is needed in the way care is delivered to patients with muscle-invasive bladder cancer to ensure more are offered treatment with curative intent, say US experts. News & Perspective ...

Pfizer's bladder cancer therapy meets main goal in late-stage study. By Reuters. January 10, 2025 3:32 PM UTC Updated January 10, 2025 Pfizer company logo is seen at a Pfizer ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. bladder cancer patients has crossed the FDA finish line as UroGen Pharma ...

At six months, Protara Therapeutics’ investigational cell therapy elicited a complete response (CR) rate of 72% among 18 patients with bladder cancer, data that sent the biotech’s shares surging.

References: Imfinzi ® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer. News release. AstraZeneca. March 31, 2025 ...